Trump''s team makes a deal with a drug company and changes rules for medical marijuana
Trump''s team makes a deal with a drug company and changes rules for medical marijuana
Introduction
President Trump said his team made a deal with a drug company called Regeneron. This is the 17th deal. Also, the government changed the rules for medical marijuana.
Main Body
The deal with Regeneron says the price of a drug called Praluent will go down. It was $537. Now it is $225. People can buy it on the TrumpRx website. In the future, Regeneron must sell its drugs in the US for the same low price as in other countries. Regeneron will also spend $27 billion to make new drugs in the US. The FDA said yes to a new medicine called Otarmeni. It is the first medicine of its kind. This is the 17th deal. Before this, 16 other drug companies made similar deals. These companies include Pfizer, AstraZeneca, and others. The details of each deal are secret. Some deals are not finished yet. A man named Kennedy explained how President Trump talks about price cuts. Kennedy said Trump uses a different way to count. For example, if a drug costs $600 and then costs $10, Trump says it is a 600% cut. But that is not normal math. In a different action, the government changed the rules for medical marijuana. It moved medical marijuana from a strict group to a less strict group. This does not make it legal under federal law. But it gives a tax break to people who sell medical marijuana. It also makes it easier to study marijuana.
Conclusion
This deal ends the first group of talks with big drug companies. But we do not know the full effect because the deals are secret. The new rules for medical marijuana are a big change, but it is still not legal under federal law. These actions show the government is trying to change drug prices and drug rules.
Vocabulary Learning
Sentence Learning
Trump Administration Concludes 17th Drug Pricing Agreement with Regeneron and Reclassifies Medical Marijuana
Introduction
President Donald Trump announced a drug pricing agreement with Regeneron Pharmaceuticals, completing a series of 17 deals with major pharmaceutical companies. Separately, the administration issued an order reclassifying state-licensed medical marijuana under a less restrictive drug schedule.
Main Body
According to a White House fact sheet, the agreement with Regeneron includes a price reduction for the cholesterol drug Praluent from $537 to $225 for patients using the TrumpRx website. Furthermore, all future Regeneron medicines will follow Most Favored Nation pricing, which means their U.S. costs will match those in other countries. Regeneron also promised to invest $27 billion in drug development in the U.S. and announced FDA approval of Otarmeni, the first gene therapy under a new voucher program. This deal is the 17th and final one in a series that began in July 2025, when President Trump sent letters to 17 major pharmaceutical companies demanding lower prices. By the end of January 2026, 16 other companies, including Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk, had signed similar agreements. However, the specific terms of each deal remain private, and some may not be finalized yet. Health and Human Services Secretary Robert F. Kennedy Jr. explained President Trump''s method of describing drug price reductions. During a Senate hearing, Kennedy stated that Trump uses a non-standard way to calculate percentage reductions. For example, reducing a drug''s price from $600 to $10 is described by Trump as a ''600 percent reduction.'' Kennedy acknowledged that this calculation does not follow conventional mathematical rules. In a separate policy action, the administration issued an executive order signed by Acting Attorney General Todd Blanche. This order reclassifies state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. The change does not legalize marijuana under federal law, but it changes its regulatory status. As a result, licensed medical marijuana operators can now claim a significant tax deduction, and barriers to cannabis research are reduced. This reclassification represents a notable shift in federal drug policy.
Conclusion
The Regeneron agreement ends the administration''s first round of drug pricing talks with major pharmaceutical companies. However, because the terms of the deals are confidential, their full effect remains unclear. The reclassification of medical marijuana is a significant change in federal regulatory policy, although it does not change the drug''s legal status. Both actions show ongoing efforts to address drug pricing and drug policy, but details about how they will be put into practice are still emerging.
Vocabulary Learning
Sentence Learning
Trump Administration Concludes 17th Drug Pricing Agreement with Regeneron and Reclassifies Medical Marijuana
Introduction
President Donald Trump announced a drug pricing agreement with Regeneron Pharmaceuticals, completing a series of 17 deals with major pharmaceutical companies. Separately, the administration issued an order reclassifying state-licensed medical marijuana under a less restrictive drug schedule.
Main Body
The agreement with Regeneron, as detailed in a White House fact sheet, includes a reduction in the price of the cholesterol-lowering treatment Praluent to $225 from $537 for patients purchasing through the TrumpRx website. Additionally, all future Regeneron medicines will be subject to Most Favored Nation (MFN) pricing, aligning their U.S. costs with those in other countries. Regeneron also committed to investing $27 billion in drug development within the United States and announced that the U.S. Food and Drug Administration had approved Otarmeni, the first gene therapy authorized under the agency’s new National Priority Voucher program. This agreement represents the 17th and final deal in a series initiated by the White House in July 2025, when President Trump sent letters to 17 major pharmaceutical companies demanding lower drug prices. By the end of January 2026, 16 other companies—including Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, and others—had signed similar agreements. The specific terms of each deal remain private, and some may not yet be finalized. Health and Human Services Secretary Robert F. Kennedy Jr. provided an explanation for President Trump’s characterization of drug price reductions. During a Senate hearing, Kennedy stated that Trump uses a non-standard method of calculating percentage reductions. He cited an example: reducing a $600 drug to $10 is described by Trump as a “600 percent reduction,” a calculation that Kennedy acknowledged departs from conventional mathematical norms. In a separate policy action, the administration issued an executive order signed by Acting Attorney General Todd Blanche that reclassifies state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. This change does not legalize marijuana under federal law but alters its regulatory status, granting licensed medical marijuana operators a significant tax deduction and reducing barriers to cannabis research. The reclassification represents a notable shift in federal drug policy.
Conclusion
The Regeneron agreement concludes the administration’s initial round of drug pricing negotiations with major pharmaceutical companies, though the confidentiality of the deals leaves their full impact uncertain. The reclassification of medical marijuana marks a substantive change in federal regulatory approach without altering its legal status. Both measures reflect ongoing efforts to address drug pricing and drug policy, with implementation details still emerging.